Bellevue Group’s Atrium Therapeutics RNA Stock Holding History

Bellevue Group’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-263,096	Closed	-$3.52M	–	172
2026 Q1	$3.52M	Buy	+263,096	New	+$3.7M	0.08%	74

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bellevue Group's RNA Position: Q2 2026 in Review

Bellevue Group sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 263,096 shares — an estimated $3.52M sold.

Bellevue Group first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $3.52M in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Bellevue Group reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
Bellevue Group sold 263,096 Atrium Therapeutics shares in Q2 2026, an estimated $3.52M.
Bellevue Group first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
Bellevue Group's Atrium Therapeutics position peaked at $3.52M in Q1 2026.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.